Current Studies
BI Trial No. 1378-0005
A study to test whether different doses of BI 690517 alone or in combination with empagliflozin improve kidney function in people with chronic kidney disease
Status: Enrolling
Type of Study: Randomized, double-blind, placebo-controlled therapy
Study Length: 14 weeks
Target Age/Sex: Over 18 years, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://clinicaltrials.gov/ct2/show/NCT03165240
Description:
Randomized, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease
ANJ900D3501
A randomized, multicenter, double-blind, parallel-group, placebo- and comparator-controlled study to compare the glycemic effects, safety, and tolerability of Metformin hydrochloride delayed-release tablets in patients with type 2 Diabetes Mellitus with varying renal function from normal up to CKD3b
Status: Enrolling
Type of Study: Randomized, double-blind, placebo-controlled therapy
Study Length: 14 weeks
Target Age/Sex: Over 18 years, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://clinicaltrials.gov/ct2/show/NCT03165240
Description:
Randomized, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chronic kidney disease
STABILIZE-CKD
Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with CKD and Hyperkalemia or at Risk of Hyperkalemia
Status: Enrolling
Type of Study: A Phase 3, International, Randomized, Double-Blind,
Placebo Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Patients with CKD and Hyperkalemia or at Risk of Hyperkalemia
Study Length: 28 months
Target Age/Sex: Over 18 years, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://clinicaltrials.gov/ct2/show/NCT05056727
Description:
This is a Phase 3, international, randomized withdrawal, double-blind, parallel-group, placebo-controlled study, to evaluate the effect of SZC as adjunct to RAASi therapy (lisinopril or valsartan) in slowing CKD progression in participants with CKD and hyperkalemia or at risk of hyperkalemia.
Specifically, the study will include participants with hyperkalemia (S-K > 5.0 to ≤ 6.5 mmol/L by central laboratory) who are on adequate or limited RAASi therapy due to hyperkalemia, and participants with normokalaemia (S-K ≥ 3.5 to ≤ 5.0 mmol/L by central laboratory) who are on limited RAASi therapy due to high risk of hyperkalemia. High risk of hyperkalemia is defined as (1) participants with a previous medical history or record of hyperkalemia within the prior 24 months who are on limited RAASi therapy despite indication in CKD; (2) participants in whom RAASi therapy is indicated in CKD but are on limited RAASi therapy and have S-K ≥ 4.7 to ≤ 5.0 mmol/L; and (3) participants in whom RAASi therapy has been discontinued or reduced to suboptimal doses because of hyperkalemia.